Design And Development Of Sustain Release Nanosponges Formulation Of Rosiglitazone

Abstract

The present study focuses on the design and development of a sustained release nanosponge formulation of Rosiglitazone, an antidiabetic agent. Nanosponges were prepared using the emulsion solvent diffusion method, and various formulations (F1–F6) were evaluated for percentage yield, entrapment efficiency, particle size, zeta potential, and morphological characteristics. Among them, formulation F3 exhibited the highest entrapment efficiency (80.33 ± 0.15%) and optimum particle size (124.32 ± 0.45 nm). In vitro drug release studies indicated a sustained release pattern, with F3 achieving 98.85% cumulative release over 12 hours and following Higuchi kinetics (R² = 0.9543). Antidiabetic activity was evaluated by in vitro α-amylase inhibition assay, and F3 showed greater inhibition (IC₅₀ = 13.96 µg/mL) compared to standard acarbose (IC₅₀ = 17.57 µg/mL). Stability studies confirmed the physical and chemical stability of the optimized formulation under different storage conditions over three months. These findings suggest that nanosponge-based delivery of Rosiglitazone offers a promising approach for sustained antidiabetic therapy.